BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair

In this episode of Global Economic Press, Alex Brady discusses the strategic appointment of Jodi Ungrodt to the Board of Directors of BioStem Technologies, where she will serve as Chair of the Audit Committee. This move is seen as a significant step in BioStem's expansion and innovation efforts, particularly in the field of advanced wound care and regenerative medicine. Ungrodt brings nearly three decades of financial leadership experience, having advised life sciences companies on public offerings, business combinations, and regulatory compliance during her tenure at Ernst and Young. Her expertise is expected to bolster BioStem's governance as the company plans to expand its business and raise its profile in public markets by 2026. BioStem Technologies is a leading medical technology company focused on developing, manufacturing, and commercializing placental-derived products for advanced wound care. The company is recognized for its proprietary allograft portfolio, derived from donated birth tissue, and its commitment to preserving the tissue's natural properties. As Audit Committee Chair, Ungrodt will oversee financial reporting, internal controls, and risk management practices, drawing on her extensive experience in the life sciences sector. For more information about BioStem Technologies and its innovative solutions, visit their website at BioStem Technologies.